A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT05156047 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Hypersomnia

Interventions

DRUG: Open-label pitolisant
DRUG: Double-blind placebo
DRUG: Double-blind pitolisant

Sponsor

Harmony Biosciences Management, Inc.